Care Oncology announces its first publication in a peer-reviewed journal
Care Oncology is pleased to announce the publication of its preliminary results in treating patients suffering from glioblastoma. Using a combination of off-patent medicines which collectively target cancer metabolism, the Care Oncology protocol is used as an adjunctive treatment alongside patients’ standard of care (SoC) cancer therapies, working in conjunction with the NHS (or other primary treatment providers). The treatment was administered by experienced doctors with specific training in the use of these medicines in an oncology setting concurrent with the SoC that patients were receiving at any point in time.
The data was analysed by an independent auditing company (Cytel Inc.). Survival outcomes from a group of 95 patients were compared to results from Public Health England database. Furthermore, Care Oncology’s approach of using old drugs which are known to be safe was validated, as side-effects were generally manageable.
Care Oncology is an evidence-driven organisation, and therefore the first peer-reviewed publication from the clinic focuses on how reliable evidence can be obtained from a real-world setting and combined with evidence from other sources to derive a complete picture of causality, safety and efficacy. This approach is important for many reasons:
- It offers a way forward to unlock the potential of old medicines in new indications (such as cancer).
- The establishment of a centre specialised in the adjunctive metabolic treatment of cancer ensures medical oversight for patient safety and allows deep learning from the clinical data.
- The clinical use of off-patent medicines offers a very low cost and useful adjunctive therapy.
Care Oncology will complete the study comparing outcomes to matched controls and undertaking additional prospective trials. Going forward, Care Oncology is planning a series of publications in glioblastoma and in other cancer types. The underlying mechanism of action of the Care Oncology treatment protocol targets a metabolic derangement which is a recognised hallmark of all cancer types. The clinic treats many other types of cancer and plans to collate data on its outcomes in ovarian, breast and pancreatic cancer, as well as other cancer types.
Dr Robin Bannister, founder of the Care Oncology Clinic and developer of the treatment commented: “It is extremely pleasing to have started to unlock the potential of repurposed drugs for cancer patients – particularly with the difficult to treat Glioblastoma population. We look forward to completing our studies and with other cancer types of different tissue of origin and are hopeful of equally positive results”
The open-access publication in Frontiers in Pharmacology can be found here (link).
*COC Protocol Patients Live Twice as Long as Those Who Receive Standard-Of-Care Alone
You Do Not Need To Travel – Available in U.S.
Independently Audited and Verified by External Biostatisticians – Currently Up For Peer Review at One of the Highest Impact Journals in the World
Treatment For ALL Cancer Patients With Disease Of Any Type Or Stage
If You Start Now
The Average COC Patient Receives Medications Within 10 Days of Initial Contact
Fill out the following form to check your immediate eligibility.
Complete your Patient Profile CLICK HERE if you’d like a same day return call from a Case Manager (7 Days a Week)
Glioblastoma Testimonial – After 12 Months “no evidence of recurrence” – COC Protocol
K.W.’s quality of life has continued to improve since the initial surgery and radiation, reporting she feels stronger and stronger as the months pass. Last winter she was able to resume teaching ski lessons and playing hockey on her local team. Her latest MRI scan, performed on May 29th, shows no evidence of recurrence. One-year post diagnosis and she remains disease free! Read Her Story
See long term Glioblastoma survivors in the news who use the COC Protocol:
Patient 1 now 4 years out post diagnosis – Featured in The Telegraph
Patient 2 now 3 years out post diagnosis – Featured in Daily Mail
A clinical trial performed in the U.K., comprised of a 95-patient cohort, resulted in a median overall survival of 27 months when the COC Protocol was used in addition to standard-of-care. Compared to median overall survival of 15.6 months¹ and 14.8 months² with standard-of-care alone.
WHAT IS THE COC PROTOCOL?
The COC Protocol is an adjunctive cancer therapy comprised of a combination of well-established, FDA-approved medications. The medications are widely prescribed, with outstanding safety profiles. Research has demonstrated significant “off-target”, anti-cancer activity of the medications individually. For example, one medication in the protocol is a drug often prescribed for people with type 2 diabetes. Many studies have demonstrated the anti-cancer activity of this drug across most types of cancer.
WHY AREN’T THESE MEDICATIONS ALREADY BEING USED?
Mostly due to financial reasons. The medications comprising the COC Protocol are “off-patent”, therefore, pharmaceutical companies are unable to re-coup the cost necessary to win approval for a new indication. Putting these well-researched medications to use for cancer immediately presents much needed therapies to cancer patients with minimal side-effects. The COC protocol was conceived to finally realize the potential of these medicines in a thoughtful, responsible, and ethical manner. Starting in London in 2013, The COC Protocol has been safely administered to over 1400 patients by trained providers through a carefully monitored program.
WHAT ARE THE ADVANTAGES TO USING EXISTING MEDICATIONS?
The use of existing medications has several advantages, the most important being safety: Decades of clinical experience have documented the safety-profile, side-effects, and drug-drug interactions of the individual medications in the COC Protocol.
WHY USE A COMBINATION OF MEDICATIONS?
It is well-accepted that complex diseases like cancer respond better to combination therapies. The medications in the COC Protocol synergistically target cancer cells through a multitude of well-established mechanisms. In general, cancer cell’s pathological multiplication is the result of two processes: First, a breakdown of the normal signaling pathways that regulate cellular division. And second, unregulated energy metabolism that fuels the uncontrolled growth of cancer cells. The COC Protocol uniquely targets both processes. By starving cancer cells of energy substrates, the COC Protocol reduces the capacity of cancer cells to defend themselves against chemotherapy and radiation. The COC protocol also acts on the many dysregulated signaling pathways within cancer cells helping to enable a process called apoptosis, or “programmed cell death,” allowing chemotherapy and radiation to kill cancer cells more effectively. Finally, medications in the COC Protocol have been shown to operate by stimulating the immune system to fight your cancer by activating an important class of immune cells called Tumor Infiltrating Lymphocytes.
WHAT IS THE PROCESS FOR STARTING THE COC PROTOCOL?
Learn How we do what we do at Care Oncology!